Handa Oncology Receives FDA Tentative Approval for OMCAZIO™ (cabozantinib) Capsules A novel 505(b)(2) alternate-salt formulation of cabozantinib designed to improve absorption, with no clinically significant food effect TAIPEI, TW / Handa Pharmaceuticals, Inc. (“Handa”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted tentative approval to OMCAZIO™ (cabozantinib) capsules, a novel alternate-salt...Read More